Lung Carcinoma
Conditions
Brief summary
This clinical trial evaluates the acceptability and effectiveness of an educational intervention (Lung Toolkit) for improving knowledge about lung cancer and lung cancer screening among American Indian/Alaskan Native (AI/AN) cigarette smokers. The Lung Toolkit is an educational intervention, including a website and a physical artifact pouch, specifically tailored to the needs of AI/AN individuals. The website includes evidence-based resources about lung health and lung cancer screening, facts about commercial tobacco and traditional tobacco, national and local smoking cessation and screening resources, and community-building resources such as stories from AI/AN community members about their experiences with lung cancer screening and smoking cessation. The physical artifact pouch links to the website with a quick response code and contains ceremonial herbs and motivational messaging around smoking cessation and lung cancer screening. The Lung Toolkit intervention may be effective for improving knowledge about lung cancer and lung cancer screening among AI/AN cigarette smokers.
Detailed description
OUTLINE: Participants receive the Lung Toolkit materials, including a link to the lung health toolkit website and a physical artifact pouch, and then receive a guided review of the Lung Toolkit materials over 60 minutes. Following the guided review, participants use the Lung Toolkit materials for 30 days.
Interventions
OTHEREducational Intervention
Receive Lung Toolkit materials
OTHERInterview
Ancillary studies
OTHERQuestionnaire Administration
Ancillary studies
Sponsors
Fred Hutchinson Cancer Center
Bristol-Myers Squibb
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Between ages 50-80 * Self-identify as AI/AN * Self-reported 10 pack-year smoking history (commercial tobacco i.e. cigarettes) * Ability to understand and willingness to sign an informed consent document
Exclusion criteria
* Not between ages 50-80 * Having less than a 10 pack-year history of smoking commercial tobacco * Inability to communicate in written and verbal English * Having any cognitive impairment that compromises the ability to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acceptability of intervention | At post-guided review assessment (day 15) and post-intervention (day 45) | Acceptability will be evaluated using the Acceptability of Intervention (AIM) assessment score and semi-structured interviews. AIM results will be summarized and presented as a range of score from 1 to 5. |
| Lung cancer screening knowledge | From baseline to day 45 | Will be evaluated using a validated measure for assessing lung cancer screening knowledge (Lung Cancer Screening Knowledge Score \[LKS\]-7). Pre- and post-intervention LKS responses will be compared via Cochran-Mantel-Haenszel and Friedman tests. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| User engagement | During 30-day use period | The effectiveness of the website in terms of engagement will be measured by tracking of bounce rate (percentage of visitors who land on website homepage and leave immediately without taking any further action, or viewing other pages). |
| User behavior | During 30-day use period | Participant behavior, and how participants navigate the website will be measured through click tracking (tracking of where users click on a website). |
| Medical mistrust | From baseline to day 45 | The intervention efficacy potential to mitigate medical mistrust will be evaluated using validated measures of discrimination and medical mistrust (Discrimination in Medical Settings; Group-Based Medical Mistrust Scale). Participant responses for each scale will be summarized with the median and range of scores at pre- and post-intervention. |
| Perceived smoking-related stigma | From baseline to day 45 | The intervention efficacy potential to reduce perceived smoking-related stigma will be evaluated using a validated measure of perceived smoking-related stigma (Cataldo Lung Cancer Stigma Scale, smoking-related subscale). Participant responses for each scale will be summarized with the median and range of scores at pre- and post-intervention. |
| Self-efficacy for lung cancer screening | From baseline to day 45 | The intervention efficacy potential to improve self-efficacy for lung cancer screening will be evaluated using a validated 9-item measure assessing self-efficacy for lung cancer screening. Participant responses for each scale will be summarized with the median and range of scores at pre- and post-intervention. |
Countries
United States
Contacts
CONTACTNicolas Anderson
PRINCIPAL_INVESTIGATORMatthew Triplette, MD, MPH
Fred Hutch/University of Washington Cancer Consortium
Outcome results
None listed